The CERS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CERS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CERS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CERS Detailed Price Forecast - CNN Money||View CERS Detailed Summary - Google Finance|
|View CERS Detailed Summary - Yahoo! Finance||View CERS Stock Research & Analysis - Zacks.com|
|View CERS Trends & Analysis - Trade-Ideas||View CERS Major Holders - Barrons|
|View CERS Call Transcripts - NASDAQ||View CERS Breaking News & Analysis - Seeking Alpha|
|View CERS Annual Report - CompanySpotlight.com||View CERS OTC Short Report - OTCShortReport.com|
|View CERS Fundamentals - TradeKing||View CERS SEC Filings - Bar Chart|
|View Historical Prices for CERS - The WSJ||View Performance/Total Return for CERS - Morningstar|
|View the Analyst Estimates for CERS - MarketWatch||View the Earnings History for CERS - CNBC|
|View the CERS Earnings - StockMarketWatch||View CERS Buy or Sell Recommendations - MacroAxis|
|View the CERS Bullish Patterns - American Bulls||View CERS Short Pain Metrics - ShortPainBot.com|
|View CERS Stock Mentions - StockTwits||View CERS Stock Mentions - PennyStockTweets|
|View CERS Stock Mentions - Twitter||View CERS Investment Forum News - Investor Hub|
|View CERS Stock Mentions - Yahoo! Message Board||View CERS Stock Mentions - Seeking Alpha|
|View Insider Transactions for CERS - SECform4.com||View Insider Transactions for CERS - Insider Cow|
|View CERS Major Holdings Summary - CNBC||View Insider Disclosure for CERS - OTC Markets|
|View Insider Transactions for CERS - Yahoo! Finance||View Institutional Holdings for CERS - NASDAQ|
|View CERS Stock Insight & Charts - FinViz.com||View CERS Investment Charts - StockCharts.com|
|View CERS Stock Overview & Charts - BarChart||View CERS User Generated Charts - Trading View|
Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association
Posted on Friday June 15, 2018
Cerus Corporation announced that results from SPARC, the Company’s European Phase 3 study evaluating the efficacy and safety of INTERCEPT-treated red blood cells in thalassemia major patients, were presented today at the 23rd Congress of European Hematology Association in Stockholm Sweden in a poster presentation entitled, “A Randomized, Controlled, Phase III Study to Evaluate S-303/Glutathione Pathogen-Inactivated ...
Cerus Corporation today announced that it will make multiple presentations, including two oral abstracts, that will be featured at the 35th International Congress of the International Society of Blood Transfusion in Toronto, Canada from June 2nd to June 6th, 2018.
Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space
Posted on Friday May 18, 2018
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Audentes Therapeutics Inc. (NASDAQ: BOLD), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Cerus Corp. (NASDAQ: CERS).
Cerus Announces Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells
Posted on Wednesday May 16, 2018
Cerus Corporation (CERS) today announced an amendment to the Company’s contract with the Biomedical Advanced Research and Development Authority (BARDA). The expansion of the agreement provides an additional $15 million in funding for supplementary support of both the ReCePI acute anemia clinical trial and SCient chronic anemia clinical trial. “BARDA is an important partner in our mission to establish INTERCEPT as the standard of care for all transfused blood components globally,” said Dr. Richard Benjamin, Cerus’ chief medical officer.